Fig. 1: Systemic pharmacokinetics and pharmacodynamics of tolododekin alfa. | Nature Communications

Fig. 1: Systemic pharmacokinetics and pharmacodynamics of tolododekin alfa.

From: Interleukin-12 anchored drug conjugate (tolododekin alfa) in patients with advanced solid tumors: first-in-human Phase 1 trial

Fig. 1

A-B Serial serum samples were obtained as per the study protocol, and the mean plasma concentration (±SD) of IL-12-ABP versus time after Cycle 1 (A) and after Cycle 2 (B) is shown, n per cohort is indicated in the figure. Systemic levels of IL-12-ABP are, in general, low, and there was a trend in dose-dependent exposure observed at higher dosing cohorts. C Levels of circulating IFN-γ are shown by treatment cohort following Cycle 1 dosing. A transient and low systemic exposure of IFN-γ with a peak at 48 h after dosing was observed. D Composite dose cohort maps summarizing the systemic levels of a panel of cytokines following treatment with repeated doses of tolododekin alfa. Tolododekin alfa treatment led to minimal changes in systemic cytokine levels, supporting the local immune activation at the injected site by tolododekin alfa. Source data can be found in the Source data file.

Back to article page